Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/4569| A serological assay to detect SARS-CoV-2 seroconversion in humans | |
| Fatima Amanat. Daniel Stadlbauer. Shirin Strohmeier. Thi Nguyen. Veronika Chromikova. Meagan McMahon. Kaijun Jiang. Guha Asthagiri-Arunkumar. Denise Jurczyszak. Jose Polanco. Maria Bermudez-Gonzalez. Giulio Kleiner. Teresa Aydillo. Lisa Miorin. Daniel Fierer. Luz Amarilis Lugo. Erna Milunka Kojic. Jonathan Stoever. Sean T.H. Liu. Charlotte Cunningham-Rundles. Philip L. Felgner. Daniel Caplivski. Adolfo Garcia-Sastre. Allen Cheng. Katherine Kedzierska. Olli Vapalahti. Jussi Hepojoki. Viviana Simon. Florian Krammer. Thomas Moran. | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| 10.1101/2020.03.17.20037713 | |
| Introduction: SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies. Methods: Here we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using recombinant antigens derived from the spike protein of SARS-CoV-2. These assays were developed with negative control samples representing pre-COVID 19 background immunity in the general population and samples from COVID19 patients. Results: The assays are sensitive and specific, allowing for screening and identification of COVID19 seroconverters using human plasma/serum as early as 3 days post symptom onset. Importantly, these assays do not require handling of infectious virus, can be adjusted to detect different antibody types and are amendable to scaling. Conclusion: Serological assays are of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic. Sensitive and specific identification of coronavirus SARS-Cov-2 antibody titers will also support screening of health care workers to identify those who are already immune and can be deployed to care for infected patients minimizing the risk of viral spread to colleagues and other patients. | |
| www.medrxiv.org | |
| 2020 | |
| Artículo | |
| https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v2.full.pdf | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 1106809.pdf | 3.31 MB | Adobe PDF | Visualizar/Abrir |